Diabetic Macular Edema Market Overview
The Diabetic Macular Edema market size was $5.05 billion in 2021 across the 7MM (seven major pharmaceutical markets). The market is forecast to achieve a CAGR of more than 8% during the forecast period.
Diabetic Macular Edema is a complication of type 1 and 2 diabetes with diabetic retinopathy. It is a leading cause of visual impairment and blindness in first-world countries, affecting over 28 million people (International Diabetes Federation, 2016; de Moura et al., 2020). The DME research report provides an overview of DME – including epidemiology, disease etiology, and management. The report will help to develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
For more insights on this report, download a free report sample
Key Regions in the Diabetic Macular Edema Market
Seven major pharmaceutical markets (7MM) covered in this report are the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. The US has the largest market share.
Diabetic Macular Edema Market, by Regions
For more regional insights, download a free report sample
DME Market Drivers
An increase in therapies with a longer duration of action, such as Kodiak Science’s KSI-301, means fewer treatment days, consequently improving patient compliance for DME patients who already experience heavy treatment burdens. In addition, the diabetic population is set to grow in line with the increased prevalence of risk factors such as obesity. Such factors will drive market growth in the coming years.
DME Market Barriers
Expensive therapies will face reimbursement challenges in markets where cost-conscious decisions are increasingly implemented. In addition, the inferior efficacy of pipeline agents will continue to leave many patients without adequate suppression of angiogenesis. This may hamper the growth of the market in focus in the coming years.
Classifications in the DME Market
DME is commonly classified as either focal (fDME) or diffuse (dDME). Diagnostic techniques used to diagnose DME subsets include optical coherence tomography (OCT) and fluorescein angiography (FA).
FDME
fDME involves fluid leaking from dilated capillaries and retinal microaneurysms. This is mainly associated with internal damage of BRB and presents as retinal fluid collection only in the outer retina. fDME may further be characterized by the presence of hard exudates.
DDME
DDME, on the other hand, consists of fluid leaking from the entire foveal circumference. This is mainly associated with external damage to the BRB; extensive capillary leakage leads to retinal fluid collection in the inner retina. dDME patients may also be susceptible to cystoid macular edema.
Key Pipeline Products in the DME Market
Diabetic Macular Edema has Ranibizumab, Aflibercept, Bevacizumab, Dexamethasone, Fluocinolone Acetonide, Triamcinolone Acetonide, Ranibizumab Biosimilar, and Nepafenac in the pipeline.
Key Players in the DME Market
Some of the key players in the Diabetic Macular Edema market are Novartis, Bayer, Alcon, Abbvie, and Regeneron.
Market Report Overview
| Market size (2021 in 7MM) | $5.05 billion |
| CAGR (2021 – 2031) | >8% |
| Classifications | FDME and DDME |
| Key Products | Ranibizumab, Aflibercept, Bevacizumab, Dexamethasone, Fluocinolone Acetonide, Triamcinolone Acetonide, Ranibizumab Biosimilar, and Nepafenac |
| Key players | Novartis, Bayer, Alcon, Abbvie, and Regenron |
Scope
- Overview of DME – including epidemiology, disease etiology and management.
- Topline DME drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
- Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
- Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global DME therapeutics market. Insightful review of the key industry drivers and barriers.
Key Highlights
DME market will grow significantly during the forecast period, at a CAGR of 8.2%.
Late-stage pipeline therapies are anticipated to drive growth in the DME market.
Reducing treatment burden is an important unmet need for DME.
Reasons to buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global DME therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Diabetic Macular Edema market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global DME therapeutics market from 2021-2031.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Stakeholders
Table of Contents
Tables
Table 1: DME – key metrics in the 7MM
Table 2: Classifications of DME as distinguished via FA
Table 3: Classifications of DME as outlined by the International Council of Ophthalmology
Table 4: Risk factors and comorbid conditions associated with DME
Table 5: Treatment guidelines for DME
Table 6: Marketed drugs for DME in the 7MM, 2021
Table 7: Top 10 deals by value, 2016–21
Table 8: DME market – global drivers and barriers, 2021–31
Table 9: Key events impacting sales for DME in the US, 2021–31
Table 10: DME Market – drivers and barriers in the US, 2021–31
Table 11: Key events impacting sales for DME in the 5EU, 2021–31
Table 12: DME Market – drivers and barriers in the 5EU, 2021–31
Table 13: Key events impacting sales for DME in Japan, 2021–31
Table 14: DME market – drivers and barriers in Japan, 2021–31
Table 15: High-prescribing physicians (non-KOLs) surveyed, by country
Graphs
Figure 1: Global sales forecast by country for DME in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in DME during the forecast period
Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of DME during the forecast period
Figure 4: Pathogenic processes in DME
Figure 5: Pathogenic processes in DME
Figure 6: 7MM, diagnosed prevalence of DME (%), men and women, ages ≥20 years, 2021
Figure 7: 7MM, sources used and not used to forecast the diagnosed prevalent cases of DME
Figure 8: 7MM, sources used to forecast the diagnosed prevalent cases of DME by involvement of the eye
Figure 9: 7MM, sources used to forecast the diagnosed prevalent cases of DME by type
Figure 10: 7MM, diagnosed prevalent cases of DME, N, both sexes, ages ≥20 years, 2021
Figure 11: 7MM, diagnosed prevalent cases of DME by age group, N, both sexes, 2021
Figure 12: 7MM, diagnosed prevalent cases of DME by sex, N, ages ≥20 years, 2021
Figure 13: 7MM, diagnosed prevalent cases of DME by involvement of the eye, N, both sexes, ages ≥20 years, 2021
Figure 14: 7MM, diagnosed prevalent cases of DME by type, N, both sexes, ages ≥20 years, 2021
Figure 15: Treatment algorithm for DME
Figure 16: Unmet needs and opportunities in DME
Figure 17: Overview of the development pipeline in DME
Figure 18: Key late-stage trials for the promising pipeline agents that GlobalData expects to be licensed for DME in the 7MM during the forecast period
Figure 19: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of DME during the forecast period
Figure 20: Competitive assessment of the pipeline anti-VEGF inhibitor drugs benchmarked against the standard of care, Eylea, and of the pipeline corticosteroid drugs benchmarked against Ozurdex
Figure 21: Analysis of the company portfolio gap in DME during the forecast period
Figure 22: Global (7MM) sales forecast by country for DME in 2021 and 2031
Figure 23: Sales forecast by therapeutic class for DME in the 7MM, 2021 and 2031
Figure 24: DME sales forecast in the 7MM by drug, 2021 and 2031
Figure 25: Sales forecast by drug for DME in the US in 2021 and 2031
Figure 26: Sales forecast by drug for DME in the 5EU in 2021 and 2031
Figure 27: Sales forecast by drug for DME in Japan in 2021 and 2031








